Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities

A new series of naphthyl chalcones ( 3a – 3p ) and their pyrazoline derivatives ( 4a – 4h ) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicinal chemistry research 2020-10, Vol.29 (10), p.1819-1835
Hauptverfasser: Pola, Shivani, Banoth, Karan Kumar, Sankaranarayanan, Murugesan, Ummani, Ramesh, Garlapati, Achaiah
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1835
container_issue 10
container_start_page 1819
container_title Medicinal chemistry research
container_volume 29
creator Pola, Shivani
Banoth, Karan Kumar
Sankaranarayanan, Murugesan
Ummani, Ramesh
Garlapati, Achaiah
description A new series of naphthyl chalcones ( 3a – 3p ) and their pyrazoline derivatives ( 4a – 4h ) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27924) and antibacterial activity against Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109) . Compounds 3b and 3p exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound 4b with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds 3a , 3l , 4b , 4c , 4e , and 4h did not exhibit any cytotoxicity, and other compounds exhibited IC 50 values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound 4b , displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound 3h did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.
doi_str_mv 10.1007/s00044-020-02602-8
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2438213617</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2438213617</sourcerecordid><originalsourceid>FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</originalsourceid><addsrcrecordid>eNp9kc1KJDEUhQsZQUd9AVcBt5Zzk1S6q5bi-DMguJlZh1Ryo5EyaZNUQ_skPq7X7gF3LkIOh--cuzhNc8rhggMsfxUA6LoWBNBbgGj7veaQK9W1PRfwgzSQFkrIg-ZnKc8AcgmdOmzef2MJj_GclU2sT6TLOQuRlTAFm1ipswtIlomO4dpMs6khRZY8i2mNE7NPZrIpYtkSVBAyW22yeUtTiMgc5rCmyJoAnzJBNYzGVrLNtI18OnUeMdt5MgRYgkOlm8fNvjdTwZP__1Hz7-b679Vde_9w--fq8r61kg-1HaTxwrvROt8PoECOgxODA-UsdgZ74Qav-mGBo_Jj16klqEFKvuDCSxzRyaPmbNe7yul1xlL1c5pzpJNadLIXXC74kiixo2xOpWT0epXDi8kbzUF_LqB3C2haQG8X0D2F5C5UCI6PmL-qv0l9AEPqjTM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2438213617</pqid></control><display><type>article</type><title>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</title><source>SpringerLink Journals - AutoHoldings</source><creator>Pola, Shivani ; Banoth, Karan Kumar ; Sankaranarayanan, Murugesan ; Ummani, Ramesh ; Garlapati, Achaiah</creator><creatorcontrib>Pola, Shivani ; Banoth, Karan Kumar ; Sankaranarayanan, Murugesan ; Ummani, Ramesh ; Garlapati, Achaiah</creatorcontrib><description>A new series of naphthyl chalcones ( 3a – 3p ) and their pyrazoline derivatives ( 4a – 4h ) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27924) and antibacterial activity against Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109) . Compounds 3b and 3p exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound 4b with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds 3a , 3l , 4b , 4c , 4e , and 4h did not exhibit any cytotoxicity, and other compounds exhibited IC 50 values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound 4b , displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound 3h did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.</description><identifier>ISSN: 1054-2523</identifier><identifier>EISSN: 1554-8120</identifier><identifier>DOI: 10.1007/s00044-020-02602-8</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Amino acids ; Antibacterial activity ; Biochemistry ; Biomedical and Life Sciences ; Biomedicine ; Bioorganic Chemistry ; Biotechnology ; Cell lines ; Cytotoxicity ; Derivatives ; Doxorubicin ; E coli ; Hydrazine ; Hydrazines ; Hydrogen bonds ; Inorganic Chemistry ; Isoniazid ; Klebsiella ; Medicinal Chemistry ; Minimum inhibitory concentration ; Molecular docking ; NMR ; Nuclear magnetic resonance ; Original Research ; Pharmacology/Toxicology ; Spectrometry ; Substitutes ; Synthesis ; Toxicity ; Tuberculosis</subject><ispartof>Medicinal chemistry research, 2020-10, Vol.29 (10), p.1819-1835</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</citedby><cites>FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</cites><orcidid>0000-0002-6699-4744</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00044-020-02602-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00044-020-02602-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Pola, Shivani</creatorcontrib><creatorcontrib>Banoth, Karan Kumar</creatorcontrib><creatorcontrib>Sankaranarayanan, Murugesan</creatorcontrib><creatorcontrib>Ummani, Ramesh</creatorcontrib><creatorcontrib>Garlapati, Achaiah</creatorcontrib><title>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</title><title>Medicinal chemistry research</title><addtitle>Med Chem Res</addtitle><description>A new series of naphthyl chalcones ( 3a – 3p ) and their pyrazoline derivatives ( 4a – 4h ) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27924) and antibacterial activity against Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109) . Compounds 3b and 3p exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound 4b with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds 3a , 3l , 4b , 4c , 4e , and 4h did not exhibit any cytotoxicity, and other compounds exhibited IC 50 values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound 4b , displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound 3h did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.</description><subject>Amino acids</subject><subject>Antibacterial activity</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bioorganic Chemistry</subject><subject>Biotechnology</subject><subject>Cell lines</subject><subject>Cytotoxicity</subject><subject>Derivatives</subject><subject>Doxorubicin</subject><subject>E coli</subject><subject>Hydrazine</subject><subject>Hydrazines</subject><subject>Hydrogen bonds</subject><subject>Inorganic Chemistry</subject><subject>Isoniazid</subject><subject>Klebsiella</subject><subject>Medicinal Chemistry</subject><subject>Minimum inhibitory concentration</subject><subject>Molecular docking</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Original Research</subject><subject>Pharmacology/Toxicology</subject><subject>Spectrometry</subject><subject>Substitutes</subject><subject>Synthesis</subject><subject>Toxicity</subject><subject>Tuberculosis</subject><issn>1054-2523</issn><issn>1554-8120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1KJDEUhQsZQUd9AVcBt5Zzk1S6q5bi-DMguJlZh1Ryo5EyaZNUQ_skPq7X7gF3LkIOh--cuzhNc8rhggMsfxUA6LoWBNBbgGj7veaQK9W1PRfwgzSQFkrIg-ZnKc8AcgmdOmzef2MJj_GclU2sT6TLOQuRlTAFm1ipswtIlomO4dpMs6khRZY8i2mNE7NPZrIpYtkSVBAyW22yeUtTiMgc5rCmyJoAnzJBNYzGVrLNtI18OnUeMdt5MgRYgkOlm8fNvjdTwZP__1Hz7-b679Vde_9w--fq8r61kg-1HaTxwrvROt8PoECOgxODA-UsdgZ74Qav-mGBo_Jj16klqEFKvuDCSxzRyaPmbNe7yul1xlL1c5pzpJNadLIXXC74kiixo2xOpWT0epXDi8kbzUF_LqB3C2haQG8X0D2F5C5UCI6PmL-qv0l9AEPqjTM</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Pola, Shivani</creator><creator>Banoth, Karan Kumar</creator><creator>Sankaranarayanan, Murugesan</creator><creator>Ummani, Ramesh</creator><creator>Garlapati, Achaiah</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FD</scope><scope>FR3</scope><scope>M7Z</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-6699-4744</orcidid></search><sort><creationdate>20201001</creationdate><title>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</title><author>Pola, Shivani ; Banoth, Karan Kumar ; Sankaranarayanan, Murugesan ; Ummani, Ramesh ; Garlapati, Achaiah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c319t-93af2fdbcdf890503b9d29d05dce4ae82d9f5896eb5fb4457059331612f3ebed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Amino acids</topic><topic>Antibacterial activity</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bioorganic Chemistry</topic><topic>Biotechnology</topic><topic>Cell lines</topic><topic>Cytotoxicity</topic><topic>Derivatives</topic><topic>Doxorubicin</topic><topic>E coli</topic><topic>Hydrazine</topic><topic>Hydrazines</topic><topic>Hydrogen bonds</topic><topic>Inorganic Chemistry</topic><topic>Isoniazid</topic><topic>Klebsiella</topic><topic>Medicinal Chemistry</topic><topic>Minimum inhibitory concentration</topic><topic>Molecular docking</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Original Research</topic><topic>Pharmacology/Toxicology</topic><topic>Spectrometry</topic><topic>Substitutes</topic><topic>Synthesis</topic><topic>Toxicity</topic><topic>Tuberculosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pola, Shivani</creatorcontrib><creatorcontrib>Banoth, Karan Kumar</creatorcontrib><creatorcontrib>Sankaranarayanan, Murugesan</creatorcontrib><creatorcontrib>Ummani, Ramesh</creatorcontrib><creatorcontrib>Garlapati, Achaiah</creatorcontrib><collection>CrossRef</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Medicinal chemistry research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pola, Shivani</au><au>Banoth, Karan Kumar</au><au>Sankaranarayanan, Murugesan</au><au>Ummani, Ramesh</au><au>Garlapati, Achaiah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities</atitle><jtitle>Medicinal chemistry research</jtitle><stitle>Med Chem Res</stitle><date>2020-10-01</date><risdate>2020</risdate><volume>29</volume><issue>10</issue><spage>1819</spage><epage>1835</epage><pages>1819-1835</pages><issn>1054-2523</issn><eissn>1554-8120</eissn><abstract>A new series of naphthyl chalcones ( 3a – 3p ) and their pyrazoline derivatives ( 4a – 4h ) were synthesized using substituted acetophenones, substituted naphthaldehydes, and hydrazine hydrate as starting materials. All the synthesized compounds were characterized by IR, NMR, and mass spectrometric analysis and screened for antimycobacterial activity against Mycobacterium tuberculosis H37Rv (ATCC 27924) and antibacterial activity against Staphylococcus aureus (MTCC 96), Bacillus subtilis (MTCC 441), Escherichia coli (MTCC 443) and Klebsiella pneumonia (MTCC 109) . Compounds 3b and 3p exhibited significant antibacterial activity against all the tested bacterial strains. Amongst the synthesized compounds, compound 4b with 2-hydroxy-5-bromophenyl substitution at 3rd position of pyrazoline showed significant antimycobacterial activity with MIC of 6.25 µM comparable to that of standard isoniazid. The synthesized compounds were further screened for their cytotoxic activity against the MDA-MB-231 and SKOV3 cell lines. The compounds 3a , 3l , 4b , 4c , 4e , and 4h did not exhibit any cytotoxicity, and other compounds exhibited IC 50 values higher than 8 and 22 µM against MDA-MB-231 and SKOV3 cell lines, respectively, compared to 1.20 and 1.30 µM shown by standard doxorubicin. To find out the putative binding mode of significantly active and weakly active compounds, a molecular docking study was also performed. In that, the most active compound 4b , displayed a hydrogen bond interaction with docking score of −10.50 kcal/mol and energy of −44.50 weakly active compound 3h did not show any crucial hydrogen bond interaction with the surrounded amino-acid residues and revealed a docking score of −6.74 and docking energy of −42.50.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s00044-020-02602-8</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-6699-4744</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1054-2523
ispartof Medicinal chemistry research, 2020-10, Vol.29 (10), p.1819-1835
issn 1054-2523
1554-8120
language eng
recordid cdi_proquest_journals_2438213617
source SpringerLink Journals - AutoHoldings
subjects Amino acids
Antibacterial activity
Biochemistry
Biomedical and Life Sciences
Biomedicine
Bioorganic Chemistry
Biotechnology
Cell lines
Cytotoxicity
Derivatives
Doxorubicin
E coli
Hydrazine
Hydrazines
Hydrogen bonds
Inorganic Chemistry
Isoniazid
Klebsiella
Medicinal Chemistry
Minimum inhibitory concentration
Molecular docking
NMR
Nuclear magnetic resonance
Original Research
Pharmacology/Toxicology
Spectrometry
Substitutes
Synthesis
Toxicity
Tuberculosis
title Design, synthesis, in silico studies, and evaluation of novel chalcones and their pyrazoline derivatives for antibacterial and antitubercular activities
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T22%3A58%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design,%20synthesis,%20in%20silico%20studies,%20and%20evaluation%20of%20novel%20chalcones%20and%20their%20pyrazoline%20derivatives%20for%20antibacterial%20and%20antitubercular%20activities&rft.jtitle=Medicinal%20chemistry%20research&rft.au=Pola,%20Shivani&rft.date=2020-10-01&rft.volume=29&rft.issue=10&rft.spage=1819&rft.epage=1835&rft.pages=1819-1835&rft.issn=1054-2523&rft.eissn=1554-8120&rft_id=info:doi/10.1007/s00044-020-02602-8&rft_dat=%3Cproquest_cross%3E2438213617%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2438213617&rft_id=info:pmid/&rfr_iscdi=true